Nanotechnology in Global Healthcare Market - Forecasts from 2019 to 2024
It is a well established fact that the future of healthcare lies in the field of nanotechnology. The technology is set to change healthcare forever. Nanomedicine and healthcare market is expected to grow at a compound annual growth rate (CAGR) of 9.50%, rising from US$89.783 billion in 2018 to US$154.809 billion in 2024. Nanotechnology offers an opportunity to work at the same scale of several biological processes, organic molecules, and cellular mechanisms, hence providing a huge impetus for innovation in healthcare and medicine, with a plethora of advances such as drug delivery systems, implantable devices, biosensors, nanoscale therapeutics, and imaging technologies. Among these, drug delivery systems constitute a huge market-share with anticancer treatment being the major contributor.
Looking at the potential applications of nanotechnology to the healthcare sector, biopharmaceutical and medical devices companies are increasingly partnering with nanomedicine and nano healthcare start-ups. These partnerships will trigger rapid investment in R&D which, in turn, will drive the demand for nanotechnology solutions in the healthcare market. Moreover, rapid development in minimally and non-invasive surgical technologies are expected to boost this market in the upcoming years. However, lack of funding from traditional sources of finance because of asymmetric information as well as a high-risk/high-return scenario in the short-run is a major restraint in the healthcare nanotechnology market. Apart from this, dealing with strict government regulations relating to this market is another factor restraining the growth of the nanotechnology in the global healthcare market. A rapidly increasing percentage of aging population and growing cases of chronic diseases among the global population is likely to provide ample opportunities for more innovative solutions in healthcare in which nanotechnology is a sure leader.
Geographically, significant growth has been observed in US markets and is expected to be one of the market leaders as far as the growth in nanomedicine is concerned. The top emerging markets will be in the Asia-Pacific region while Africa and Middle-East will see some growth in the upcoming years. The booming medical tourism industry in India is projected to bolster the demand for nanotechnology in the healthcare market.
DRIVERS
Higher investment in R&D in nanomedicine and devices with major pharmaceutical companies tying up with nanotech start-ups.
Rapid and pervasive development in minimally and non-invasive surgical technologies.
RESTRAINTS
Asymmetric information and high risk / high-return scenario in the short run leads to less financing from traditional sources of funding.
Stricter regulations by government bodies like FDA due to safety risks posed by this technology lead to higher costs to introduce nanomedicine products in the market.
RECENT DEVELOPMENTS
In the University of Michigan, engineers are developing ways to use nanotechnology in non-invasive surgery
A Northwestern University team has developed a method of optimizing spherical nucleic acids, which could revolutionize nanomedicine for cancer immunotherapy in the future.
Lauren Sciences LLC wins AU$1 million grant award from FightMND to develop a transformative nanomedicine for brain diseases.
Segmentation
The nanotechnology in healthcare market has been analyzed through the following segments:
By Component
Nanomedicines
Nanomedical devices
By Type
Drug delivery
Nanoscale therapeutics
Biosensors
Implantable devices
Imaging devices
By Application
Oncology
Cardiovascular
Neurology
Anti-infectory
Anti-inflammatory
Others
By Geography
North America
USA
Canada
Others
South America
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Others
Middle East and Africa
Saudi Arabia
Israel
UAE
Others
Asia Pacific
Japan
South Korea
China
India
Others
Looking at the potential applications of nanotechnology to the healthcare sector, biopharmaceutical and medical devices companies are increasingly partnering with nanomedicine and nano healthcare start-ups. These partnerships will trigger rapid investment in R&D which, in turn, will drive the demand for nanotechnology solutions in the healthcare market. Moreover, rapid development in minimally and non-invasive surgical technologies are expected to boost this market in the upcoming years. However, lack of funding from traditional sources of finance because of asymmetric information as well as a high-risk/high-return scenario in the short-run is a major restraint in the healthcare nanotechnology market. Apart from this, dealing with strict government regulations relating to this market is another factor restraining the growth of the nanotechnology in the global healthcare market. A rapidly increasing percentage of aging population and growing cases of chronic diseases among the global population is likely to provide ample opportunities for more innovative solutions in healthcare in which nanotechnology is a sure leader.
Geographically, significant growth has been observed in US markets and is expected to be one of the market leaders as far as the growth in nanomedicine is concerned. The top emerging markets will be in the Asia-Pacific region while Africa and Middle-East will see some growth in the upcoming years. The booming medical tourism industry in India is projected to bolster the demand for nanotechnology in the healthcare market.
DRIVERS
Higher investment in R&D in nanomedicine and devices with major pharmaceutical companies tying up with nanotech start-ups.
Rapid and pervasive development in minimally and non-invasive surgical technologies.
RESTRAINTS
Asymmetric information and high risk / high-return scenario in the short run leads to less financing from traditional sources of funding.
Stricter regulations by government bodies like FDA due to safety risks posed by this technology lead to higher costs to introduce nanomedicine products in the market.
RECENT DEVELOPMENTS
In the University of Michigan, engineers are developing ways to use nanotechnology in non-invasive surgery
A Northwestern University team has developed a method of optimizing spherical nucleic acids, which could revolutionize nanomedicine for cancer immunotherapy in the future.
Lauren Sciences LLC wins AU$1 million grant award from FightMND to develop a transformative nanomedicine for brain diseases.
Segmentation
The nanotechnology in healthcare market has been analyzed through the following segments:
By Component
Nanomedicines
Nanomedical devices
By Type
Drug delivery
Nanoscale therapeutics
Biosensors
Implantable devices
Imaging devices
By Application
Oncology
Cardiovascular
Neurology
Anti-infectory
Anti-inflammatory
Others
By Geography
North America
USA
Canada
Others
South America
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Others
Middle East and Africa
Saudi Arabia
Israel
UAE
Others
Asia Pacific
Japan
South Korea
China
India
Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. NANOTECHNOLOGY IN HEALTHCARE MARKET BY COMPONENTS
5.1. Nanomedicine
5.2. Nanomedical devices
6. NANOTECHNOLOGY IN HEALTHCARE MARKET BY TYPE
6.1. Drug delivery
6.2. Nanoscale therapeutics
6.3. Biosensors
6.4. Implantable devices
6.5. Imaging devices
6.6. Others
7. NANOTECHNOLOGY IN HEALTHCARE MARKET BY APPLICATION
7.1. Oncology
7.2. Cardiovascular
7.3. Neurology
7.4. Anti-infectory
7.5. Anti-inflammatory
7.6. Others
8. NANOTECHNOLOGY IN HEALTHCARE MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. UAE
8.4.4. Others
8.5. Asia Pacific
8.5.1. Japan
8.5.2. South Korea
8.5.3. China
8.5.4. India
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Lauren Sciences LLC
10.2. Nanobiotics SA
10.3. Novartis AG
10.4. Gilead Sciences Inc
10.5. Amgen Inc
10.6. Pfizer Inc
10.7. Hoffman-La Roche Ltd
10.8. UCB SA
10.9. Sanofi
LIST OF FIGURES
LIST OF TABLES
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. NANOTECHNOLOGY IN HEALTHCARE MARKET BY COMPONENTS
5.1. Nanomedicine
5.2. Nanomedical devices
6. NANOTECHNOLOGY IN HEALTHCARE MARKET BY TYPE
6.1. Drug delivery
6.2. Nanoscale therapeutics
6.3. Biosensors
6.4. Implantable devices
6.5. Imaging devices
6.6. Others
7. NANOTECHNOLOGY IN HEALTHCARE MARKET BY APPLICATION
7.1. Oncology
7.2. Cardiovascular
7.3. Neurology
7.4. Anti-infectory
7.5. Anti-inflammatory
7.6. Others
8. NANOTECHNOLOGY IN HEALTHCARE MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. UAE
8.4.4. Others
8.5. Asia Pacific
8.5.1. Japan
8.5.2. South Korea
8.5.3. China
8.5.4. India
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Lauren Sciences LLC
10.2. Nanobiotics SA
10.3. Novartis AG
10.4. Gilead Sciences Inc
10.5. Amgen Inc
10.6. Pfizer Inc
10.7. Hoffman-La Roche Ltd
10.8. UCB SA
10.9. Sanofi
LIST OF FIGURES
LIST OF TABLES
